38348 Federal Register / Vol. 86, No. 136 / Tuesday, July 20, 2021 / Notices 

2 Indeed, the settlement before the Commission 

on May 14 required the divestiture of 293 fuel 

outlets, see Press Release, 7-Eleven Inc., Response 

to FTC Commissioner Statement (May 14, 2021), 

https://corp.7-eleven.com/corppress-releases/05-14- 

2021-7-eleven-inc-response-to-ftc-commissionerstatement; and the settlement unanimously 

accepted by the Commission today similarly 

requires the divestiture of 293 fuel outlets. 

Commissioners Slaughter and Chopra highlight the 

order provision that prohibits Seven & i’s subsidiary 

7-Eleven from enforcing noncompete provisions 

against current franchisees or others who might 

seek employment at the divestiture outlets. This 

narrow provision is consistent with previous 

Commission orders that impose conditions to 

ensure that divested assets have access to the 

employees necessary to ensure the success of the 

divestiture. 

3Statement of Commissioners Noah Joshua 

Phillips & Christine S. Wilson, supra note 1; Press 

Release, 7-Eleven, Inc., supra note 2. 

ample opportunity to act before the 

parties merged.2

To the extent the Analysis to Aid 

Public Comment or other statements 

issued suggest that Seven & i Holdings 

or its U.S. subsidiary 7-Eleven Inc. acted 

in bad faith, the public is free to read 

our earlier statement and Seven & i 

Holding’s side of the story,3 the veracity 

of which no commissioner has disputed 

in the month since they were issued. 

Those accounts paint a different, and 

regrettable, picture of what happened. 

We thank our staff for their diligence, 

professionalism, and responsiveness 

throughout this process; the 

Commission’s failures here are in no 

way a reflection of their efforts. 

[FR Doc. 2021–15350 Filed 7–19–21; 8:45 am] 

BILLING CODE 6750–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; Accelerating Medicine 

Partnership in Parkinson’s Disease (AMP 

PD). 

Date: July 30, 2021. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Mirela Milescu, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Activities, 

NINDS/NIH, NSC, 6001 Executive Blvd., 

Suite 3208, MSC 9529, Rockville, MD 20852, 

mirela.milescu@nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: July 15, 2021. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–15367 Filed 7–19–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Vascular and Hematology. 

Date: August 23, 2021. 

Time: 2:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892, (Virtual Meeting). 

Contact Person: Larry Pinkus, Ph.D. 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4132, 

MSC 7802 Bethesda, MD 20892, (301) 435– 

1214, pinkusl@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: July 14, 2021. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–15329 Filed 7–19–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Clinical Trial 

Planning Grant (R34 Clinical Trials Not 

Allowed) and NIAID Clinical Trial 

Implementation Cooperative Agreement (U01 

Clinical Trial Required). 

Date: August 16, 2021. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G58, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Anuja Mathew, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G58, Rockville, MD 

20852, 301–761–6911, anuja.mathew@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 


khammond on DSKJM1Z7X2PROD with NOTICES